Urgent.News

What's breaking now, across thousands of outlets.

Business

Merck KGaA is dropping a heart drug from its Silence deal after a rival's trial failed

Merck KGaA will not pursue an advanced study of zerlasiran, which lowers a cholesterol particle, after Novartis ended a similar drug

Merck KGaA is dropping a heart drug from its Silence deal after a rival's trial failed

We haven't written up this one. Quartz has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at qz.com →

More in Business

More from Thursday 12 November →